SLRNライブシグナル | Getagraph.comで利益を最大化

買う 113548 min ago

@ $7.58

発行日: 15 2月 2024 @ 00:18

リターン: -43.93%

前回のシグナル: 2月 14 - 02:30

前回のシグナル: 売る

リターン: -1.69 %

Live Chart Being Loaded With Signals

Commentary (3 5月 2024 @ 05:00):

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines...

Stats
本日の出来高	919 490
平均出来高	1.25M
時価総額	413.69M
EPS	$0 ( 2024-04-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.840
ATR14	$0.00800 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-09	Lin Shao-lee	Buy	964 829	Employee Stock Option (right to buy)
2024-01-09	Lin Shao-lee	Buy	413 498	Employee Stock Option (right to buy)
2024-01-09	Labrucherie Gil M	Buy	855 513	Employee Stock Option (right to buy)
2024-01-02	Lin Shao-lee	Sell	10 691	Common Stock
2023-12-18	Tetrault Lynn A.	Buy	89 955	Director Stock Option (right to buy)

INSIDER POWER
-1.36
Last 57 transactions
Buy: 28 627 675 \| Sell: 30 925 812

ボリューム相関

長: -0.05 (neutral)

短: 0.32 (neutral)

Signal:(50.901) Neutral

Acelyrin, Inc. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Acelyrin, Inc. 相関 - 通貨/商品

0.39
( neutral )

0.30
( neutral )

0.00
( neutral )

-0.57
( weak negative )

-0.18
( neutral )

Acelyrin, Inc. 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-12.25

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-12.25

Financial Reports:

No articles found.

Acelyrin, Inc.

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.